[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100447882":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":33,"responsibleParty":49,"collaborators":19,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":19,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":19,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":36,"whyStopped":19,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"doxycycline","EXPERIMENTAL","patients administrated with doxycycline tablets 100mg orally per day",[13],"Drug: Doxycycline Hyclate",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DRUG","Doxycycline Hyclate",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Dan Liang","Zhongshan Ophthalmic Center, Sun Yat-sen University","PRINCIPAL_INVESTIGATOR",[26,30],{"name":22,"role":27,"phone":28,"phoneExt":19,"email":29},"CONTACT","（86）-87330402","liangdan@gzzoc.com",{"name":31,"role":27,"phone":28,"phoneExt":19,"email":32},"Yuxi Chen","chenyx293@mail2.sysu.edu.cn",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":19,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Zhongshan Ophthalmic Center","RECRUITING","Guangzhou","Guangdong","China","CN",{"type":42,"coordinates":43},"Point",[44,45],113.25,23.11667,{"lat":45,"lon":44},[48],{"name":22,"role":27,"phone":28,"phoneExt":19,"email":29},{"type":24,"investigatorFullName":22,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"principal investigator","100447882","multi-model-image-of-doxycycline-in-tao-100447882",false,"NCT05112211","Multi-model Image of Doxycycline in TAO","A Multi-model Image to Evaluate the Efficacy of Doxycycline in Thyroid Associated Ophthalmopathy","Inclusion Criteria:\n\n* Informed consent\n* Age 18-70 years old\n* Diagnosed with TAO\n\nExclusion Criteria:\n\n* Sight-threatening TAO with dysthyroid optic neuropathy\n* Allergy of tetracycline\n* Have contraindications of MRI(metal pacemaker, fake teeth, foreign body and other materials which will disturb the examination)","ALL","18 Years","70 Years",{"count":62,"type":63},20,"ESTIMATED","INTERVENTIONAL",[66],"NA","This study aims to evaluate the efficacy of doxycycline treating Thyroid Associated Ophthalmopathy by multi-modal image.",[69],"Thyroid Associated Ophthalmopathy",[71,69,72,73,74],"Doxycycline","Extraorbital muscle","Orbit fat volume","Multi-modal image","2023-11-21",{"date":77,"type":78},"2023-11-22","ACTUAL",{"date":80,"type":78},"2022-01-01",{"date":82,"type":63},"2026-12-01",{"name":5,"class":6},1]